碎片化诊疗、美国外科医师学会癌症委员会认证与食管癌手术联合化疗患者的总生存
基于美国国家癌症数据库2006至2019年18502例接受食管切除术并围手术期化疗的食管癌患者,比较单中心诊疗、碎片化至癌症委员会认证机构与非认证机构的生存差异。碎片化诊疗与单中心诊疗总生存相当,但在学术中心行食管切除术与生存改善相关(校正风险比=0.82;P=0.016)。
要点
- 44.8%患者接受单中心诊疗,18.5%碎片化至癌症委员会认证机构,36.4%碎片化至非认证机构。
- 碎片化诊疗与单中心诊疗的总生存相当。
- 在学术中心行食管切除术与生存改善相关(校正风险比=0.82;P=0.016)。
核心结论
- 美国多数食管癌诊疗碎片化于多家机构,碎片化时围手术期化疗最常见于非癌症委员会认证中心。
- 在学术中心行食管切除术、在癌症委员会认证机构行围手术期治疗时总生存最佳。
研究设计与样本
- 查询美国国家癌症数据库,纳入2006至2019年接受食管切除术并围手术期化疗的食管癌患者。
- 共18502例患者符合纳入标准,分为单中心诊疗、碎片化至癌症委员会认证诊疗、碎片化至非癌症委员会认证诊疗三组。
- 采用多变量逻辑回归、Kaplan-Meier生存分析和Cox比例风险模型识别关联。
主要发现
- 8290例(44.8%)接受单中心诊疗,3414例(18.5%)碎片化至癌症委员会认证诊疗,6798例(36.4%)碎片化至非癌症委员会认证诊疗。
- 白人患者碎片化诊疗可能性更高(校正比值比=1.25;P<0.001),不毗邻大都市区的患者碎片化诊疗可能性更高(校正比值比=1.36;P<0.001)。
- 碎片化诊疗与单中心诊疗的总生存相当。
- 在学术中心行食管切除术与生存改善相关(校正风险比=0.82;P=0.016)。
- 在非学术中心行食管切除术的患者中,围手术期化疗在癌症委员会认证机构进行者总生存最佳,优于化疗在碎片化至非癌症委员会认证中心进行者(P=0.022)。
临床怎么用
- 原文结论未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Increasing regionalization for esophagectomy for cancer may lead patients to travel for surgery at one institution and receive chemotherapy at another closer to home. We explore the effects on survival for care fragmentation, the Commission on Cancer status of secondary institutions providing chemotherapy, and the type of institution performing surgery. METHODS: We queried the National Cancer Database to identify all patients who underwent esophagectomy for esophageal cancer and received perioperative chemotherapy between 2006 and 2019. Patients were divided into single-center care, fragmented-to-Commission on Cancer care, or fragmented-to-non-Commission on Cancer care. We identified associations using multivariable logistic regression, Kaplan-Meier survival analyses, and Cox proportional hazards models. RESULTS: A total of 18,502 patients met the criteria for inclusion: 8,290 (44.8%) received single-center care; 3,414 (18.5%) fragmented-to-Commission on Cancer care; and 6,798 (36.4%) fragmented-to-non-Commission on Cancer care. Fragmented care was more likely in White patients (adjusted odds ratio = 1.25; P < .001) and in patients nonadjacent to a metropolitan area (adjusted odds ratio = 1.36; P < .001). Overall survival was equivalent between single-center and fragmented care, but undergoing an esophagectomy at an academic center was associated with improved survival (adjusted hazard ratio = 0.82; P = .016). In patients with an esophagectomy at a nonacademic center, overall survival was best if perioperative chemotherapy was administered at Commission on Cancer-accredited facilities compared with chemotherapy at fragmented-to-non-Commission on Cancer centers (P = .022). CONCLUSION: Most of the esophageal cancer care in the US is fragmented at multiple institutions. When care is fragmented, it is most commonly at non-Commission on Cancer centers for perioperative chemotherapy. Overall survival is best when esophagectomy is performed at an academic center, and perioperative therapy is administered at Commission on Cancer-accredited facilities.
引用
- Verm RA, Baker MM, Cohn T, et al. Fragmented care, Commission on Cancer accreditation, and overall survival in patients receiving surgery and chemotherapy for esophageal cancer. Surgery. 2023. PMID: 37743107. doi:10.1016/j.surg.2023.07.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。